Aoxin Q & M Dental Group Addresses Shareholder Concerns Ahead of 2026 AGM and EGM

Aoxin Q & M Dental Group Limited (“the Company”), a leading dental services provider primarily operating in China, has released detailed responses to shareholder queries ahead of its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) scheduled for 27 April 2026. The responses, which cover board composition, governance, recent regulatory developments, financial oversight, and capital strategy, contain several key points that could be of particular interest to investors.

Key Points and Potentially Price-Sensitive Information

• Board Composition and Independence Under Scrutiny
  • The Company is facing significant board changes, with Mr Chua Ser Miang set to be redesignated as Non-Executive Non-Independent Chairman, and the retirement of two independent directors, Prof Chew Chong Yin and Mr Lin Ming Khin. This will leave the Board with only one independent director (Mr Chong Eng Wee), raising concerns about compliance with the Code of Corporate Governance and independent oversight.
  • The Nominating Committee (NC) and Board have committed to appointing two additional Independent Non-Executive Directors (INEDs) to restore board independence. A candidate for INED and Audit Committee chairman has already been shortlisted, and due diligence is ongoing. Investors should watch for imminent announcements regarding these appointments.
  • The Company has emphasized its interim governance processes, including Board committees, internal controls, and director recusals from conflict situations to safeguard minority shareholder interests until new INEDs are appointed.
• Questions About Director Commitments and Conflicts
  • Concerns were raised about Mr Chong Eng Wee’s ability to fulfill his duties given his directorships in seven other listed companies and active legal practice. The Board and NC defended his capacity, citing his attendance record, relevant experience, and support structure at his law firms.
  • Questions were also posed about potential conflicts of interest, particularly regarding Mr Chong’s role as an INED at Quantum Healthcare Limited, a company potentially overlapping with Q&M’s dental business. The Board stated there are no direct conflicts as Quantum’s operations are based in Singapore while Aoxin Q & M operates primarily in Liaoning, China, and emphasized separate governance structures.
• Financial Reporting and Regulatory Compliance in China
  • The Group disclosed a revenue overstatement of approximately RMB6.2 million in the previous financial year due to non-compliance with PRC medical insurance regulations (Yi Bao) at two hospitals. This followed a self-review prompted by the National Healthcare Security Administration (NHSA). The Board stated these findings were not systemic, but has undertaken enhanced oversight, engaged external advisors, and increased compliance training.
  • NHSA/Yi Bao claims accounted for about 30% of the Primary Healthcare segment’s FY2025 turnover, highlighting the materiality of compliance in this area to the Group’s revenues.
• China Regulatory Risks and “Red-Chip” Structure
  • The Board provided reassurance that recent regulatory changes in China regarding offshore listings and “red-chip” structures do not materially affect the Group’s current structure or ability to repatriate dividends. The Group continues to monitor regulatory developments which could impact future M&A activities in China.
• Capital Management and Fund Deployment
  • The Group’s cash position has increased, with further funds expected from an ongoing placement exercise. The Board has placed excess cash in interest-bearing accounts and short-term deposits, but is also evaluating higher-yielding short-term instruments, considering liquidity and risk factors.
  • The Board has considered various financing options for M&A, including asset-backed and equity-based funding. It recently opted for placements due to regulatory complexities in China regarding asset-backed financing. The November 2025 rights issue was heavily oversubscribed at S\$0.03/share, but with the share price now around S\$0.20, the Board cautions that future rights issues may not see similar demand.
• Remuneration and Performance Shares for Non-Executive Directors
  • Shareholders questioned the proposed performance share awards to non-executive directors Dr Ng Chin Siau and Ms Ng Sook Hwa, as their performance criteria include executive-like targets such as M&A execution. The Board clarified their roles are strictly non-executive, providing strategic guidance, and that the awards are designed to incentivize board-level contributions, not executive management.
  • Concerns about overlapping incentives at both Aoxin Q & M and Q&M Dental Group were addressed, with the Remuneration and PSP Committee asserting independent assessment of awards at the Company level. Non-conflicted directors maintain their recommendation for these awards.
• Management Structure and CEO Appointment
  • The Group currently operates with four Deputy CEOs overseeing distinct functions and a Group General Manager and Deputy General Manager who report to the Board. The Board believes this structure is efficient for current operations and is in the process of identifying a suitable Group CEO.
• Substantial Shareholder Reporting
  • Some individuals previously listed as substantial shareholders, including former executive directors Dr Shao Yongxin and Dr Ong Siew Hwa, no longer appear due to their holdings falling below the 5% threshold and no longer being directors. The Company confirmed compliance with disclosure requirements.

Investor Takeaways

• The upcoming board changes and temporary lack of majority independent directors may weigh on investor sentiment until new INEDs are appointed and announced.
• Reassurances about regulatory compliance in China and no current restructuring needs may help mitigate concerns about country-specific risks.
• Continued focus on prudent capital management and an openness to various financing options supports the Group’s M&A ambitions and financial flexibility.
• The Board’s responses on director commitments, conflicts, and remuneration reflect awareness of corporate governance scrutiny, which is critical for investor confidence.
• The large proportion of revenue tied to PRC medical insurance and the recent overstatement may prompt investors to closely monitor internal controls and future disclosures on regulatory compliance.

Conclusion

The Board’s comprehensive responses to shareholder questions highlight ongoing governance, regulatory, and strategic developments that could have implications for Aoxin Q & M Dental Group’s share price. Investors should pay close attention to forthcoming announcements on board appointments, regulatory updates from China, and the Group’s evolving capital allocation strategy, as these could impact both operational performance and market perception.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or seek professional guidance before making investment decisions. The information herein is based on publicly available documents and may be subject to change.

View Aoxin Q & M Historical chart here